Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F C Hamdy

Showing results (81-90 of 104) with videos related to

Pageof 11
Sort By:
British Journal of Cancer|January 1, 1994
Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasiaF C Hamdy, E J Fadlon, D Cottam, et al.
Prostate Cancer and Prostatic Diseases|June 3, 2009
PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysisA Murad, S J Lewis, G Davey Smith, et al.
Scientific Reports|October 1, 2013
Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancerG Mathew, A Mitchell, J M Down, et al.
Cancer Epidemiology|September 13, 2011
A comparison of prostate cancer survival in England, Norway and Sweden: a population-based studyL Holmberg, D Robinson, F Sandin, et al.
British Journal of Cancer|November 11, 1999
The effects of transurethral resection and cystoprostatectomy on dissemination of epithelial cells in the circulation of patients with bladder cancerF Desgrandchamps, M Teren, L Dal Cortivo, et al.
The Journal of Clinical Endocrinology and Metabolism|January 13, 2004
Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease?D Gunnell, S E Oliver, J L Donovan, et al.
Verhandlungen Der Deutschen Gesellschaft Fur Pathologie|September 18, 2007
[Mutation of the FGFR3 oncogene is an independent and favorable prognostic factor for tumor-specific survival in patients with urothelial carcinoma of the upper urinary tract]M Burger, J Catto, J van Oers, et al.
British Journal of Cancer|July 29, 2004
S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursorsI Rehman, S S Cross, A-R Azzouzi, et al.
British Journal of Cancer|April 8, 2010
Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy resultR C Macefield, C Metcalfe, J A Lane, et al.
Journal of Medical Genetics|July 6, 2004
Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinomaM Roupret, J Catto, F Coulet, et al.
Pageof 11

Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
British Journal of Cancer|January 1, 1994
Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasiaF C Hamdy, E J Fadlon, D Cottam, et al.
Prostate Cancer and Prostatic Diseases|June 3, 2009
PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysisA Murad, S J Lewis, G Davey Smith, et al.
Scientific Reports|October 1, 2013
Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancerG Mathew, A Mitchell, J M Down, et al.
Cancer Epidemiology|September 13, 2011
A comparison of prostate cancer survival in England, Norway and Sweden: a population-based studyL Holmberg, D Robinson, F Sandin, et al.
British Journal of Cancer|November 11, 1999
The effects of transurethral resection and cystoprostatectomy on dissemination of epithelial cells in the circulation of patients with bladder cancerF Desgrandchamps, M Teren, L Dal Cortivo, et al.
The Journal of Clinical Endocrinology and Metabolism|January 13, 2004
Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease?D Gunnell, S E Oliver, J L Donovan, et al.
Verhandlungen Der Deutschen Gesellschaft Fur Pathologie|September 18, 2007
[Mutation of the FGFR3 oncogene is an independent and favorable prognostic factor for tumor-specific survival in patients with urothelial carcinoma of the upper urinary tract]M Burger, J Catto, J van Oers, et al.
British Journal of Cancer|July 29, 2004
S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursorsI Rehman, S S Cross, A-R Azzouzi, et al.
British Journal of Cancer|April 8, 2010
Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy resultR C Macefield, C Metcalfe, J A Lane, et al.
Journal of Medical Genetics|July 6, 2004
Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinomaM Roupret, J Catto, F Coulet, et al.
Pageof 11